Abstract
Summaryo1.The rationale for treatment of hypercholesterolemia has been presented.2.The results with previous methods of therapy have been briefly reviewed.3.We have 33 patients under treatment with MER-29, an inhibitor of cholesterol biosynthesis.4.There has been a reduction in the serum cholesterol in 11 of 15 patients treated for more than two months, and in 4 of 9 patients under therapy for less than two months.5.The only suggestions of toxicity have been a slight change in the SGOT of one patient whose values returned to normal with continued treatment, and an increase of one plus to four and back to two plus in the floeculation of another patient.6.There is, to date, no evidence from this study of appreciable interference with the esterification of cholesterol.7.It is planned to continue treatment and studies to a total of six months to evaluate the results more completely. The rationale for treatment of hypercholesterolemia has been presented. The results with previous methods of therapy have been briefly reviewed. We have 33 patients under treatment with MER-29, an inhibitor of cholesterol biosynthesis. There has been a reduction in the serum cholesterol in 11 of 15 patients treated for more than two months, and in 4 of 9 patients under therapy for less than two months. The only suggestions of toxicity have been a slight change in the SGOT of one patient whose values returned to normal with continued treatment, and an increase of one plus to four and back to two plus in the floeculation of another patient. There is, to date, no evidence from this study of appreciable interference with the esterification of cholesterol. It is planned to continue treatment and studies to a total of six months to evaluate the results more completely.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call